Industry-Sponsored Symposia

Challenges in Treating Oral Mucosal Inflammatory Diseases
– An Emerging New Therapy 

Sponsored by Dermtreat ApS

Wednesday, 26 July 2017
14:00 – 15:00

Chairs: Ronald Wolf, Marburg, Germany
Lars Siim Madsen, Copenhagen, Denmark

A broad variety of oral mucosal inflammatory diseases exist and common for most of them is the lack of approved standard treatments, why various treatment regimens are being used including corticosteroids, anesthetics, analgesics, anti-microbial, anti-histamines ect.
The major challenges in treating oral mucosal inflammatory diseases are:

• Short contact time/low exposure

o Dilution/dissolvent by salvia and movement/contact (jaw, tongue and teeth)

The Rivelin patch provide a new ground breaking therapy for medications targeting mucosal ulcers, erythema and stomatitis.
The first generation of the Rivelin patch is an electrospun clobetasol containing patch. The clobetasol containing patch, Rivelin-Clo will profiled in a phase 2 study enrolling 240 patients suffering of Oral lichen planus. The study will launch by the end og 2017.

Smartphones for Skin Cancer Screening: The future?
Sponsored by SkinVision

Thursday, 27 July 2017
08:00 – 08:45


Novel Targets for the Treatment of atopic Dermatitis
Sponsored by Chugai Pharmaceutical Co., Ltd.

Thursday, 27 July 2017
14:00 – 15:00

Chair: Thomas Ruzicka, Munich, Germany 
14:00  Pathophysiology of pruritus in atopic dermatitis
Martin Steinhoff, Dublin, Ireland
14:30 New biologics for the treatment of atopic dermatitis
Andreas Wollenberg, Munich, Germany


Patient Management in Atopic Dermatitis: Current Practice and Future Prospects
Sponsored by Sanofi Genzyme

Friday, 28 July 2017
14:00 – 15:00

Chair: Diamant Thaçi, Luebeck, Germany
14:00  Introduction
Diamant Thaçi, Luebeck, Germany
14:05 Atopic Dermatitis: From pathophysiology to patient burden
Diamant Thaçi, Luebeck, Germany
14:30 What can be done now and in the future to reduce patient burden of atopic dermatitis?
Michael Cork, Sheffield, UK
14:50 Question & answers session
Diamant Thaçi, Luebeck, Germany
Michael Cork, Sheffield, UK